Speaker 0: There's a small circle of people who truly understand what it takes to lead a health system right now. The decisions are enormous. The variables are constantly shifting, and the stakes of getting a call wrong don't stay contained. That's not a complaint. It's a structural reality. And it's why the most effective c suite leaders are deliberate about where do they go to pressure test their thinking. Becker's fourteenth annual CEO and CFO roundtable brings together more than 1,500 executive level attendees and nearly 400 speakers for four days built around growth, financial sustainability, workforce strategy, and the leadership questions that don't have easy answers. Join us November second through the fifth in Chicago. For the agenda and event details, visit beckershospitalreview.com and click on the events tab in the upper right. Speaker 1: Hello, and thank you so much for tuning in to the Becker's Oncology Leadership Podcast. I'm Elizabeth Gregersen, a reporter here at Becker's. And today, I am talking to Alicia Cruz, vice president of the Orlando Health Cancer Institute. Alicia, thank you so much for taking the time to speak with me today. Speaker 2: No. Absolutely. Thank you for taking the time to talk to me. It's been an absolute pleasure getting to know you through Becker's Oncology. Speaker 1: Aw. Thank you so much. I know. I'm always grateful to share your insights, so I'm excited that our podcast audience now gets to meet you. Before I dive into my questions, I'd love if you could share a bit about just your background and your role at Orlando Health for our listeners. Speaker 2: Absolutely. So I've been in health care operations leadership for about twenty six years. I think I've done every specialty beyond ortho, and I'm gonna leave that alone other than ortho oncology. But about sixteen years ago, I ended up losing my brother to colon cancer and decided I needed to leave the Northeast, applied to a job in the Sunshine State, at the University of Miami to just get out of the Northeast gray. And within nine months, got kind of lured over to talk about a role at a can the cancer institute, so at Sylvester. And just absolutely took a dive, considered it a sign, and for the first time in health care, really fell in love with what I was doing. So I've been in oncology ever since. And, there's no looking back for me. This is my passion plus purpose role. I get to create for patients and their families in everything that we do. And now I also enjoy really building up leaders and building teams and doing startup programs. So it's become a true passion plus purpose career, and I plan to stay oncology for the long haul. Speaker 1: Amazing. Thank you so much. And and as you kind of hint at some of the things you're most excited about that you're working on, at Orlando Health, are you able to narrow it down to maybe what your biggest priority is right now? Speaker 2: Yes. Absolutely. As we've seen in throughout the state of Florida, and I'm assuming it's everywhere, a lot of population growth, which also means a lot of cancer diagnoses, early cancer diagnosed, late stage still in much earlier populations like younger populations. So for me, it's access, making sure that if someone is thinking that they have cancer or quickly getting to someone who is diagnosed, like, making sure they can get into the door and meet with an expert to alleviate that anxiety. You know, we keep getting bigger and bigger, but sometimes when you get larger and larger, you forget that that that critical time window of getting someone in, is the most important thing you can do. And if you can't do it, they will vote with their feet and go somewhere whether they have better quality, worse quality. They are not looking at scores. They're looking at how can I get in and who did my neighbor go and see and how quickly can I get into them, so they can alleviate that fear of what does this mean for me? So we are heavily focused on access right now and making sure that time window is the right window. And then in some of those diagnoses that, you know, you've been in the oncology space for a long time, we are not MD Anderson or Sloan Kettering where we only take a cancer diagnosis. We also have a lot of workup opportunities and a lot of referrals that may not to be or they might be high risk. So just making sure those are appropriately kind too. So just making sure that we're getting patients throughout the communities in which we serve in a timely essence, really taking care of their needs. So the other piece of that is access to clinical trials. Right? So in oncology today, if you don't have trials, you're really not offering the treatment you should be offering the way that we continue to evolve. So if you're doing tomorrow's treatments today, that means you're offering the robust clinical trial portfolio. And that's something we have hyper focused on as well, making sure that our patients don't have to go outside of their community, outside of their state to get the same access to the latest and greatest, the innovative, the Till therapy, the you know, any of the things that are not your typical standard of care at this point. So those are our big ones. So access and then, of course, clinical trial access and having a portfolio that matches our community. Speaker 1: Absolutely. And I I think the way you, you phrased it with, you know, patients will vote with their feet and walk somewhere else, I think, is something, you know, leaders across all specialties can can relate to, specifically when it comes to, you know, oncology service lines and cancer centers. You mentioned kind of the growing patient population, clinical trials. So those might be incorporated in your answer to the question I'm about to ask you. But is there any kind of pressure that you feel cancer centers are facing right now that is not getting talked about enough? Speaker 2: I don't know that it's not being talked about, but globally being shared, just in passing a few just seeing leaders and being on some exchanges. The drug shortages that are happening right now, the growing drug expense where some of your smaller we're lucky we're a large system. We've got that benefit of a very large supply chain to help us negotiate, you know, at a large scale and then also having that inventory. But I think it was earlier this week, we were on a leadership exchange, and some of the smaller programs are really struggling and having to stratify if we only have, say, 30 doses, what 30 patients are we gonna be able to give this to? How do you pick? Right? Because you have 60 patients. And those choices are very difficult. So I think people are feeling it and struggling, and, they're each struggling in their own arena right now. So I think that's always a hard one. And we're gonna see more of that as the drug expenses seem to continue to grow up. And, of course, everything we're doing right now, all the new developments, some of those drugs are very expensive. When you look at cellular therapy and gene therapy, they're not cheap. So making sure you have the team behind that so you don't get stuck with a huge expense. And, yes, you you gave someone life altering treatment, but then you also incurred an expense with no reimbursement. That is a scary dilemma in the wrong, like, environment. So I think around the drugs and expenses and where we're going, that's one complication and pressure. Then there's always this staffing challenge. It's just a very different working group at this point. You have a new generation of folks who they really do love that work life integration. And post COVID, when it's complicated, sometimes they'll just jump ship and go do something else. So keeping that team to support, you know, the physicians and APPs are not the ones that typically jump every one or two years. But building that really strong team around you to be able to deliver the care, that continues to be a challenge. Even in the systems where, you know, you have great benefits and you might pay competitively. If if there's the assumption or the feeling perception that it's complicated, then they can do the same thing working in a less complex specialty, we still lose them every day. So for the long haul, I think that's where we start to dive into the AI space. Right? When you have less of those experts who are staying to support the team, Speaker 1: How do you how do Speaker 2: you have the systems around that? So instead of just humans, you've got the tech to help with some of the workflow. Speaker 1: Absolutely. And I'd love to kind of pick your brain about how you're navigating AI right now. You know, I know everyone kind of has a different mindset, different strategy. I think, overall, I've heard there's places where it's, you know, changing the game and then other times where maybe it's overhyped. Safety concerns, of course, are always the caveat everybody shares their opinion with, but I I'd love to to see how you are looking at AI right now. Speaker 2: Yeah. Absolutely. I think for our system, overarching, Orlando Health has been at the cutting edge kind of they've been there and trying to make sure that we have the most innovation in every space. So that's been great for us because we've been able to turn on our AI lung incidental program, which then now can be turned on for other modalities. And what that did was identify patients that you would miss. You know, they showed up to the ED after a car crash. And it's something showed on a chest except, but no one was looking for an incidental. Right? So finding a lung cancer early, that's pretty incredible. We have AI turned on within our EMR to help, you know, the infusion capacity piece. It's huge. Where we used to think we were full because you had people manually trying to arrange a schedule. Well, you take that out and let the tech come in and all of a sudden, you 30% more volume without going into overtime, without stretching your nurses too much over lunch, all of the things. Huge impact there. Of course, there's 7,000 solutions for every problem you have. So trying to find the right vendor or player or stakeholder to work with you within your EMR and within your system, it's not quick. So turning some of those on took a while, And you see some of the vendors, you know, now they're starting to absorb one another. So it gets a little complex. And for us, we never like to operate outside of our EMR too much because once you have to log in to something else, that's more clicks, that's more logins, that's more everything. So we're pretty straightforward with our IT governance and steering committees, and they also have an AI governance committee. So they really sets out the things that are not appropriate from a safety lens and what is doable from an IT lens for us. But when it's really important, say, for our specialty, we do have a chief informatics officer that's also a head and neck surgeon on our team. And so we together, we kind of vet out what will work, what won't work, and we've been able to be nimble by having all the right stakeholders there. We are blessed and that we have a strong oncology informatics team. So when we do finally get that green light, we can implement fairly quickly. Usually, it's that pre process that, you know, it has to go to supply chain, has to go to finance, has to go all around, get vetted out. But Yeah. I I really pride our organization on allowing us to use these tools because the the inbox management for the team messaging, you know, handling patient messages, that reduces their time. The things that they're finding for screenings and incidentals, that just identifies patients early. Puts it in a workable list. So it's pretty incredible what it can do. And then our system turned on, for us, Copilot, and now we have access to Claude and ChatGPT. So how that reduces even the administrator burden. Right? Mhmm. Nespar need this. Hey. What are the last 15 emails I've missed? Can you summarize who I need to get back to? And it's taking hours of days. So then you can spend it purposely rounding with your teams and finding out what do you need, what do you not need, what's broken. So I think it's completely shifting how we do our work as administrators too. Speaker 1: Perfect. And I love all those concrete examples because I know our listeners love them as well of just how, you know, the technology is actually changing things in your day to day, you know, workflow and and broader, you know, when it comes to diagnostics and everything. So I'm excited to see what what comes next out of Orlando Health there. Yeah. Absolutely. Yeah. And I'm kind of phrasing this question to leaders as a forward looking leadership question. So when you look towards the next generation of oncology leaders who maybe are just joining the field or on their way up, is there a challenge that you think will be left in their hands that they're going to need to solve that maybe the field hasn't fully tackled yet or isn't taking seriously enough today that you see the future generation having to face? Speaker 2: Yeah. It's gonna sound old school, but with all of the tech and how fast we are moving, really making sure we still keep that balance of a personal touch and the communication. It you know, you can send me 7,000,000 emails in a day, but if if I'm out there and I'm supposed to be rounding on teams and talking to them and sharing information, it's just the the speed of which we're getting all of this new info and how quickly you can not communicate important things to the entire group. So every time we have our town halls or med staff meetings or our pod meetings, you find out that you think you've communicated things well and everyone is up to speed, but there's so much information coming at everyone. You do have to have those intentional conversations. So it's I've said it a few times in the last two years. It's almost like back to basics. Don't forget that personal touch to find out what is working with your patients, what is working with your teams. And we find sometimes that, okay. Great. Now we have this new tool that helps us send more MyChart messages to patients. Some patients hate using MyChart and messaging. They would prefer you call them back, but instead they're getting a message and they have six more questions. So it's really not losing sight of how are we making sure we're communicating to everyone in the way they receive communication and not assuming. Yeah. It's Speaker 1: kind of like don't let the pendulum swing all the way in the other direction. Kind of find that that happy middle ground. Speaker 2: Exactly. Speaker 1: And if anyone's listening to the podcast, I'm sure you know what my last question is gonna be. I always like to ask the oncology leaders what is giving them hope when they look towards the future of cancer care and what, you know, is giving them optimism about what oncology will look like in the next years. I'd love to hear your perspective. Speaker 2: For me, I keep calling it the most exciting time to be in this space because, you know, you you hear people you talk and, like, I'm from a small town back in Illinois, and I go home and they're like, oh, yeah. You guys don't wanna cure cancer. You just wanna keep treating so you can make money. But they don't understand the science and what has been discovered and what is going on. And to I was telling my mom a few months ago, like, went to a Caris talk and, you know, you're treating two patients with the same treatment and they're not having the same results. Well, now you can do a liquid biopsy or different testing and find out, well, yeah, the one's not responding because it's a completely different cancer with a completely different genetic system and mutation that's impacting how they, you know, they receive treatment. And so being able to get precision medicine and get down to treating that person based on their genetic makeup and that biopsy is pretty phenomenal. And even watching what they've done in the melanoma space, watching terminal, stage four terminal melanoma patients suddenly having a chance of, like, they're completely eradicating their cancer. Just went through this with one of my best friends, my old neighbor in Miami, last year December telling me, oh my god. I have metastatic melanoma, and I think this is it. And two months ago, finding out that he's in remission, cancer free, and he was on a trial down in Miami, and that is what gives me hope about what we're doing and where we're headed, and it's just an exciting time to see that impact. Speaker 1: Absolutely. And I think, you know, being able to to talk about your friends and and and have that connection of all these kind of broader innovations and the excitement about the future and and tying it back to, you know, your friend and and the patients that Orlando Health is serving is is such a great way to end the podcast. So I'm grateful, for you looping us in on that, and I hope your friend's doing well. But thank Speaker 2: you so much. And that's why it's it's such a personal connection to the field and such an exciting time to help. So just honored to serve in the role. Speaker 1: Absolutely. Well, thank you again, Alicia, for coming on the podcast and taking the time to share your insights with our audience. Speaker 2: Truly a pleasure. Thank you for having me.